Biology of prostate-specific antigen.

Urology

Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital (UMAS), Malmö, Sweden.

Published: November 2003

AI Article Synopsis

  • The human kallikrein family on chromosome 19 includes prostate-specific antigen (PSA) and other serine proteases, which are important for prostate cancer detection, but much about their functions is still unclear.
  • Regulatory mechanisms governing PSA, particularly how it interacts with alpha1-antichymotrypsin and alpha2-macroglobulin, may provide valuable insights into prostate cancer diagnosis and progression.
  • Emerging evidence suggests that other kallikreins like hK2, hK4, and hK15 might help convert pro-PSA into active PSA, indicating their potential role in tumor control and suggesting changes in screening and treatment strategies could improve early detection of prostate cancer.

Article Abstract

The human kallikrein (hk) family, located on chromosome 19, encodes prostate-specific antigen (PSA [or hK3]), hK2, hK4, and hK15 (prostin), as well as other serine proteases. Although PSA has been used in the detection of prostate cancer for several years, much remains unknown about its function and forms. The regulatory mechanisms of PSA are vital to its understanding. A particular mechanism by which PSA forms complexes with either alpha1-antichymotrypsin or alpha2-macroglobulin may provide important information for disease detection and progression. Data are emerging that show that active hK2, hK4, and hK15 may be important to convert pro-PSA to the active PSA enzyme. This information, along with insights into the precise mechanisms of PSA expression, may be used to suggest that PSA and, perhaps, other members of the hK family contribute critical control mechanisms to tumor invasion or progression. Although much remains to be revealed on the role of these gene products in the detection and progression of prostate cancer, findings from studies that show sensitive signaling of the disease > or =20 years before the diagnosis of clinically significant prostate cancer may alter screening procedures and improve treatment options.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0090-4295(03)00775-1DOI Listing

Publication Analysis

Top Keywords

prostate cancer
12
prostate-specific antigen
8
hk2 hk4
8
hk4 hk15
8
mechanisms psa
8
detection progression
8
psa
7
biology prostate-specific
4
antigen human
4
human kallikrein
4

Similar Publications

Coding Variants of the Genitourinary Development Gene Carry High Risk for Prostate Cancer.

JCO Precis Oncol

January 2025

Medical Research Service, Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN.

Purpose: Considerable genetic heterogeneity is currently thought to underlie hereditary prostate cancer (HPC). Most families meeting criteria for HPC cannot be attributed to currently known pathogenic variants.

Methods: To discover pathogenic variants predisposing to prostate cancer, we conducted a familial case-control association study using both genome-wide single-allele and identity-by-descent analytic approaches.

View Article and Find Full Text PDF

Neuroendocrine neoplasms (NENs) encompass a diverse set of malignancies with limited precision therapy options. Recently, therapies targeting DLL3 have shown clinical efficacy in aggressive NENs, including small cell lung cancers and neuroendocrine prostate cancers. Given the continued development and expansion of DLL3-targeted therapies, we sought to characterize the expression of DLL3 and identify its clinical and molecular correlates across diverse neuroendocrine and non-neuroendocrine cancers.

View Article and Find Full Text PDF

Objective: A new library of Thiazolidine-2,4-dione-biphenyl Derivatives derivatives (10a-j) was designed and synthesized. All compounds were characterized by spectral data. Further, these were evaluated for their in vitro anticancer activity.

View Article and Find Full Text PDF

Objective: This study aimed to investigate the influence of p16 immunohistochemical expression on the biochemical recurrence rate of pT2-pT3 prostate cancer.

Materials And Methods: A total of 488 pT2-pT3 stage prostate adenocarcinomas undergoing radical prostatectomy were included in this study. Following a review of Gleason classification and retrieval of sociodemographic and clinicopathological data, as well as the date of last consultation and biochemical recurrence, immunohistochemistry for p16 was performed.

View Article and Find Full Text PDF

Among the known nuclear exportins, CRM1 is the most studied prototype. Dysregulation of CRM1 occurs in many cancers, hence, understanding the role of CRM1 in cancer can help in developing synergistic therapeutics. The study investigates how CRM1 affects prostate cancer growth and survival.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!